3 results
8-K
EX-99.3
ELTX
Elicio Therapeutics Inc.
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
the market. The key competitive factors affecting the success of all of Elicio’s programs are likely to be product safety, efficacy, convenience
S-4/A
EX-10.26
ELTX
Elicio Therapeutics Inc.
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
of Regeneron Product safety and/or efficacy and Sponsor’s compliance with this Agreement with respect to the Regeneron Product. Such requests for review
- Prev
- 1
- Next